Kumar Budur, Chief Medical Officer of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), filed a Form 4 on September 9, 2026, disclosing a series of open-market sales and stock option exercises in common stock between September 4 and September 8, 2026.
Key Highlights
- September 4 sale: Budur disposed of 5,500 shares at a weighted average price of $41.9839, with individual transactions ranging from $41.51 to $42.32.
- September 8 sales: Three separate sale transactions disposed of 4,500 shares (weighted average $42.2475), 1,000 shares (weighted average $42.7947), and 22,954 shares (weighted average $43.1014).
- Option exercises: On September 8, 2026, Budur exercised stock options covering 12,200 shares at $30.69 and 10,754 shares at $30.27, both at a derivative price of $0.
- Remaining ownership: Following all reported transactions, Budur directly held 13,115 shares of common stock.
- Rule 10b5-1 plan: According to the filing, all sales were effected pursuant to a Rule 10b5-1 trading plan.
- Remaining options: After the exercises, Budur retained 30,300 stock options at $30.69 and 64,246 stock options at $30.27, both held directly.
Details of Budur's Transactions in Harmony Biosciences Common Stock
According to the filing, Kumar Budur, serving as Chief Medical Officer at Harmony Biosciences Holdings, Inc., reported six transactions in the company's common stock across two trading days. On September 4, 2026, Budur sold 5,500 shares at a weighted average price of $41.9839, with actual sale prices ranging from $41.51 to $42.32 across multiple transactions. Following that sale, beneficial ownership stood at 18,615 shares held directly.
On September 8, 2026, Budur exercised two stock options prior to conducting further sales. The first exercise covered 12,200 shares under an option with an exercise price of $30.69, expiring January 24, 2034. The second exercise covered 10,754 shares under an option priced at $30.27, expiring May 1, 2034. The filing notes that both options vest 25% on an initial date and then ratably on a quarterly basis until the fourth anniversary of the grant date, subject to continued service. The derivative price for both exercises was reported as $0.
Also on September 8, Budur sold 4,500 shares at a weighted average of $42.2475 (range $41.59 to $42.57), 1,000 shares at a weighted average of $42.7947 (range $42.59 to $43.02), and 22,954 shares at a weighted average of $43.1014 (range $43.00 to $43.20). All sales were disclosed as having been made pursuant to a Rule 10b5-1 trading plan, as noted in the filing's explanation of responses. After all reported transactions, Budur's direct beneficial ownership in common stock was 13,115 shares.
What Was Disclosed
The filing reported four sales totaling 33,954 shares and two stock option exercises totaling 22,954 shares by Harmony Biosciences' Chief Medical Officer between September 4 and September 8, 2026, all conducted under a pre-established Rule 10b5-1 trading plan.






Please wait processing your request...